Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 01:00PM ET
1.54
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.85 Insider Own17.08% Shs Outstand58.88M Perf Week0.00%
Market Cap90.68M Forward P/E- EPS next Y-0.94 Insider Trans0.00% Shs Float48.83M Perf Month-11.49%
Income-46.06M PEG- EPS next Q-0.24 Inst Own29.00% Short Float0.65% Perf Quarter-14.92%
Sales0.07M P/S1295.36 EPS this Y-18.15% Inst Trans-18.47% Short Ratio1.28 Perf Half Y-42.11%
Book/sh1.92 P/B0.80 EPS next Y5.99% ROA-38.05% Short Interest0.32M Perf Year-19.37%
Cash/sh1.69 P/C0.91 EPS next 5Y- ROE-44.37% 52W Range1.14 - 7.25 Perf YTD-5.52%
Dividend Est.- P/FCF- EPS past 5Y9.74% ROI-40.35% 52W High-78.76% Beta1.28
Dividend TTM- Quick Ratio5.82 Sales past 5Y0.00% Gross Margin-1532.65% 52W Low35.09% ATR (14)0.13
Dividend Ex-Date- Current Ratio6.50 EPS Y/Y TTM-19.90% Oper. Margin-91543.05% RSI (14)46.07 Volatility9.20% 8.97%
Employees66 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin-67135.73% Recom1.40 Target Price8.01
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-57.16% Payout- Rel Volume0.89 Prev Close1.54
Sales Surprise-99.95% EPS Surprise-43.92% Sales Q/Q- EarningsMar 21 BMO Avg Volume247.51K Price1.54
SMA20-5.26% SMA50-4.05% SMA200-39.50% Trades Volume124,374 Change0.00%
Date Action Analyst Rating Change Price Target Change
Apr-05-23Upgrade Guggenheim Neutral → Buy $8
Feb-28-22Downgrade Guggenheim Buy → Neutral
Oct-28-21Upgrade Raymond James Outperform → Strong Buy $10 → $14
Mar-11-21Upgrade Guggenheim Neutral → Buy $16
Nov-06-20Upgrade SVB Leerink Mkt Perform → Outperform $7 → $10
Oct-08-20Initiated H.C. Wainwright Buy $11
Jun-17-20Initiated BTIG Research Buy $12
Apr-30-20Upgrade Raymond James Mkt Perform → Outperform
Jun-05-19Downgrade SunTrust Buy → Hold $55 → $5
Jun-05-19Downgrade Robert W. Baird Outperform → Neutral $58 → $6
Mar-21-24 11:53AM
08:45AM
07:00AM
Mar-19-24 07:30AM
Feb-22-24 07:30AM
07:30AM Loading…
Jan-25-24 07:30AM
Jan-04-24 07:00AM
Dec-01-23 09:55AM
Nov-28-23 09:35AM
Nov-06-23 09:35AM
07:30AM
Nov-01-23 07:30AM
Oct-31-23 07:12PM
Sep-11-23 07:00AM
Sep-01-23 02:38PM
10:15AM Loading…
Aug-31-23 10:15AM
Aug-30-23 07:30AM
Aug-10-23 07:30AM
Jun-28-23 07:30AM
Jun-21-23 07:00AM
May-11-23 07:30AM
May-03-23 07:14AM
Apr-18-23 04:01PM
Apr-14-23 04:01PM
Apr-13-23 11:22AM
Apr-11-23 09:08PM
04:00PM
Apr-07-23 10:21AM
Apr-05-23 11:57AM
10:49AM
04:14PM Loading…
Apr-04-23 04:14PM
02:55PM
Mar-23-23 08:21AM
Mar-22-23 07:30AM
Jan-05-23 07:30AM
Dec-21-22 07:30AM
Nov-09-22 07:40AM
07:30AM
Sep-29-22 07:30AM
Sep-09-22 07:30AM
Sep-08-22 07:30AM
Sep-07-22 10:54AM
Aug-17-22 12:00PM
Aug-11-22 12:00PM
Aug-05-22 07:00AM
Jul-26-22 03:36PM
07:30AM
Jul-06-22 07:30AM
Jun-29-22 12:02PM
07:30AM
May-17-22 07:30AM
May-13-22 01:55PM
May-12-22 07:30AM
Mar-31-22 02:56PM
07:30AM
Mar-24-22 08:55AM
07:30AM
Mar-17-22 10:03AM
07:30AM
Mar-08-22 07:30AM
Feb-28-22 12:10PM
07:30AM
Feb-16-22 07:30AM
Feb-08-22 07:30AM
Jan-10-22 07:30AM
Jan-05-22 08:00AM
Nov-15-21 03:39PM
07:30AM
Nov-11-21 07:30AM
Nov-08-21 06:17AM
Nov-05-21 07:30AM
Nov-03-21 07:30AM
Oct-28-21 09:51AM
09:49AM
07:10AM
07:03AM
Oct-27-21 07:30AM
Oct-19-21 10:08AM
07:30AM
Oct-12-21 07:30AM
Sep-09-21 07:30AM
Sep-08-21 07:30AM
Aug-10-21 09:17AM
07:30AM
Aug-06-21 07:30AM
Aug-05-21 07:30AM
Jul-28-21 03:45PM
Jun-17-21 07:30AM
Jun-08-21 07:30AM
May-30-21 05:22AM
May-21-21 07:30AM
May-12-21 07:30AM
07:15AM
May-11-21 04:30PM
Apr-15-21 07:30AM
Mar-25-21 06:30AM
Mar-03-21 07:30AM
Mar-01-21 04:01PM
01:54AM
Feb-25-21 08:30AM
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.